Bladder Cancer Metastasis Induced by Chronic Everolimus Application Can Be Counteracted by Sulforaphane In Vitro
Abstract
:1. Introduction
2. Results
2.1. Cell Adhesion
Acute and Chronic Treatment
2.2. Chemotactic Activity under Acute Versus Chronic Drug Application
2.3. Surface Expression of CD44 Splice Variants
2.4. CD44 Knock-down
2.5. Surface and Protein Expression of Integrin Subtypes
2.6. Integrin Blockade
3. Discussion
4. Materials and Methods
4.1. Cell Cultures
4.2. Drug Application
4.3. Cell Adhesion to Collagen Matrix
4.4. Chemotaxis and Migration
4.5. CD44 Expression Analysis
4.6. Integrin Surface Expression
4.7. Western Blot Analysis
4.8. Integrin Receptor Blockade
4.9. CD44 Knock-down
4.10. Statistics
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
Abbreviations
MDPI | Multidisciplinary Digital Publishing Institute |
DOAJ | Directory of open access journals |
SFN | Sulforaphane |
HDAC | Histone deacetylase |
mTOR | mechanistic target of rapamycin |
FAK | focal adhesion kinase |
p | phosphorylated |
References
- Fujii, Y. Prediction models for progression of non-muscle-invasive bladder cancer: A review. Int. J. Urol. 2018, 25, 212–218. [Google Scholar] [CrossRef] [Green Version]
- Kobayashi, T. Understanding the biology of urothelial cancer metastasis. Asian J. Urol. 2016, 3, 211–222. [Google Scholar] [CrossRef] [Green Version]
- Carneiro, B.A.; Meeks, J.J.; Kuzel, T.M.; Scaranti, M.; Abdulkadir, S.A.; Giles, F.J. Emerging therapeutic targets in bladder cancer. Cancer Treat. Rev. 2015, 41, 170–178. [Google Scholar] [CrossRef] [PubMed]
- Li, X.; He, S.; Tian, Y.; Weiss, R.M.; Martin, D.T. Synergistic inhibition of GP130 and ERK signaling blocks chemoresistant bladder cancer cell growth. Cell. Signal. 2019, 63, 109381. [Google Scholar] [CrossRef]
- Sathe, A.; Nawroth, R. Targeting the PI3K/AKT/mTOR pathway in bladder cancer. Methods Mol. Biol. 2018, 1655, 335–350. [Google Scholar]
- Tian, T.; Li, X.; Zhang, J. mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy. Int. J. Mol. Sci. 2019, 20, E755. [Google Scholar] [CrossRef] [Green Version]
- Burrell, R.A.; Swanton, C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol. Oncol. 2014, 8, 1095–1111. [Google Scholar] [CrossRef]
- Schuerger, N.; Klein, E.; Hapfelmeier, A.; Kiechle, M.; Brambs, C.; Paepke, D. Evaluating the demand for integrative medicine practices in breast and gynecological cancer patients. Breast Care 2019, 14, 35–40. [Google Scholar] [CrossRef]
- Irmak, Z.; Tanrıverdi, Ö.; Ödemiş, H.; Uysal, D.D. Use of complementary and alternative medicine and quality of life of cancer patients who received chemotherapy in Turkey. Complement. Ther. Med. 2019, 44, 143–150. [Google Scholar] [CrossRef] [PubMed]
- Giannopoulou, A.F.; Velentzas, A.D.; Konstantakou, E.G.; Avgeris, M.; Katarachia, S.A.; Papandreou, N.C.; Kalavros, N.I.; Mpakou, V.E.; Iconomidou, V.; Anastasiadou, E.; et al. Revisiting histone deacetylases in human tumorigenesis: The paradigm of urothelial bladder cancer. Int. J. Mol. Sci. 2019, 20, E1291. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sanaei, M.; Kavoosi, F. Histone deacetylases and histone deacetylase inhibitors: Molecular mechanisms of action in various cancers. Adv. Biomed. Res. 2019, 8, 63. [Google Scholar] [PubMed]
- Shukla, S.; Penta, D.; Mondal, P.; Meeran, S.M. Epigenetics of breast cancer: Clinical status of epi-drugs and phytochemicals. Adv. Exp. Med. Biol. 2019, 1152, 293–310. [Google Scholar] [PubMed]
- Mastuo, T.; Miyata, Y.; Yuno, T.; Mukae, Y.; Otsubo, A.; Mitsunari, K.; Ohba, K.; Sakai, H. Molecular mechanisms of the anti-cancer effects of isothiocyanates from cruciferous vegetables in bladder cancer. Molecules 2020, 25, E575. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Juengel, E.; Najafi, R.; Rutz, J.; Maxeiner, S.; Makarevic, J.; Roos, F.; Tsaur, I.; Haferkamp, A.; Blaheta, R.A. HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells. Oncotarget 2017, 8, 110016–110028. [Google Scholar] [CrossRef] [Green Version]
- Fan, P.; Zhang, Y.; Liu, L.; Zhao, Z.; Yin, Y.; Xiao, X.; Bauer, N.; Gladkich, J.; Mattern, J.; Gao, C.; et al. Continuous exposure of pancreatic cancer cells to dietary bioactive agents does not induce drug resistance unlike chemotherapy. Cell Death Dis. 2016, 7, e2246. [Google Scholar] [CrossRef] [Green Version]
- Juengel, E.; Nowaz, S.; Makarevi, J.; Natsheh, I.; Werner, I.; Nelson, K.; Reiter, M.; Tsaur, I.; Mani, J.; Harder, S.; et al. HDAC-Inhibition counteracts everolimus resistance in renal cell carcinoma In Vitro by diminishing cdk2 and cyclin A. Mol. Cancer 2014, 13, 152. [Google Scholar] [CrossRef] [Green Version]
- Lai, C.J.; Lin, C.Y.; Liao, W.Y.; Hour, T.C.; Wang, H.D.; Chuu, C.P. CD44 promotes migration and invasion of docetaxel-resistant prostate cancer cells likely via induction of hippo-yap signaling. Cells 2019, 8, E295. [Google Scholar] [CrossRef] [Green Version]
- Kashyap, T.; Pramanik, K.K.; Nath, N.; Mishra, P.; Singh, A.K.; Nagini, S.; Rana, A.; Mishra, R. Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3β signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer. Oral Oncol. 2018, 86, 234–243. [Google Scholar] [CrossRef]
- Li, C.; Zhou, Y.; Peng, X.; Du, L.; Tian, H.; Yang, G.; Niu, J.; Wu, W. Sulforaphane inhibits invasion via activating ERK1/2 signaling in human glioblastoma U87MG and U373MG cells. PLoS ONE 2014, 9, e90520. [Google Scholar] [CrossRef] [Green Version]
- Jeong, Y.J.; Cho, H.J.; Chung, F.L.; Wang, X.; Hoe, H.S.; Park, K.K.; Kim, C.H.; Chang, H.W.; Lee, S.R.; Chang, Y.C. Isothiocyanates suppress the invasion and metastasis of tumors by targeting FAK/MMP-9 activity. Oncotarget 2017, 8, 63949–63962. [Google Scholar] [CrossRef] [Green Version]
- Rutz, J.; Juengel, E.; Euler, S.; Maxeiner, S.; Justin, S.; Roos, F.; Chun, F.K.; Blaheta, R.A. Chronic sulforaphane application does not induce resistance in renal cell carcinoma cells. Anticancer Res. 2018, 38, 6201–6207. [Google Scholar] [CrossRef]
- Tai, Y.L.; Lai, I.R.; Peng, Y.J.; Ding, S.T.; Shen, T.L. Activation of focal adhesion kinase through an interaction with β4 integrin contributes to tumorigenicity of colon cancer. FEBS Lett. 2016, 590, 1826–1837. [Google Scholar] [CrossRef] [PubMed]
- Justin, S.; Rutz, J.; Maxeiner, S.; Chun, F.K.; Juengel, E.; Blaheta, R.A. Chronic sulforaphane administration inhibits resistance to the mTOR-inhibitor everolimus in bladder cancer cells. Int. J. Mol. Sci. 2020, 21, 4026. [Google Scholar] [CrossRef] [PubMed]
- Zhang, H.; Brown, R.L.; Wei, Y.; Zhao, P.; Liu, S.; Liu, X.; Deng, Y.; Hu, X.; Zhang, J.; Gao, X.D.; et al. CD44 splice isoform switching determines breast cancer stem cell state. Genes Dev. 2019, 33, 166–179. [Google Scholar] [CrossRef] [PubMed]
- Wei, L.; Yin, F.; Chen, C.; Li, L. Expression of integrin α-6 is associated with multi drug resistance and prognosis in ovarian cancer. Oncol. Lett. 2019, 17, 3974–3980. [Google Scholar] [CrossRef] [Green Version]
- Hu, T.; Zhou, R.; Zhao, Y.; Wu, G. Integrin α6/Akt/Erk signaling is essential for human breast cancer resistance to radiotherapy. Sci. Rep. 2016, 6, 33376. [Google Scholar] [CrossRef] [PubMed]
- Cheuk, I.W.; Siu, M.T.; Ho, J.C.; Chen, J.; Shin, V.Y.; Kwong, A. ITGAV targeting as a therapeutic approach for treatment of metastatic breast cancer. Am. J. Cancer Res. 2020, 10, 211–223. [Google Scholar]
- Wang, H.; Chen, H.; Jiang, Z.; Lin, Y.; Wang, X.; Xiang, J.; Peng, J. Integrin subunit alpha V promotes growth, migration, and invasion of gastric cancer cells. Pathol. Res. Pract. 2019, 215, 152531. [Google Scholar] [CrossRef]
- Liu, Y.R.; Yin, P.N.; Silvers, C.R.; Lee, Y.F. Enhanced metastatic potential in the MB49 urothelial carcinoma model. Sci. Rep. 2019, 9, 7425. [Google Scholar] [CrossRef] [Green Version]
- Dai, L.; Chai, C.M.; Shen, T.Y.; Tian, Y.; Shang, Z.Q.; Niu, Y.J. LncRNA ITGB1 promotes the development of bladder cancer through regulating microRNA-10a expression. Eur. Rev. Med. Pharmacol. Sci. 2019, 23, 6858–6867. [Google Scholar]
- Li, M.; Jiang, X.; Wang, G.; Zhai, C.; Liu, Y.; Li, H.; Zhang, Y.; Yu, W.; Zhao, Z. ITGB4 is a novel prognostic factor in colon cancer. J. Cancer 2019, 10, 5223–5233. [Google Scholar] [CrossRef]
- Stewart, R.L.; West, D.; Wang, C.; Weiss, H.L.; Gal, T.; Durbin, E.B.; O’Connor, W.; Chen, M.; O’Connor, K.L. Elevated integrin α6β4 expression is associated with venous invasion and decreased overall survival in non-small cell lung cancer. Hum. Pathol. 2016, 54, 174–183. [Google Scholar] [CrossRef] [Green Version]
- Beaulieu, J.F. Integrin α6β4 in colorectal cancer: Expression, regulation, functional alterations and use as a biomarker. Cancers 2019, 12, E41. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pawlik, A.; Słomińska-Wojewódzka, M.; Herman-Antosiewicz, A. Sensitization of estrogen receptor-positive breast cancer cell lines to 4-hydroxytamoxifen by isothiocyanates present in cruciferous plants. Eur. J. Nutr. 2016, 55, 1165–1180. [Google Scholar] [CrossRef] [Green Version]
- Kaczyńska, A.; Świerczyńska, J.; Herman-Antosiewicz, A. Sensitization of HER2 positive breast cancer cells to lapatinib using plants-derived isothiocyanates. Nutr. Cancer 2015, 67, 976–986. [Google Scholar] [CrossRef]
- Juengel, E.; Meyer dos Santos, S.; Schneider, T.; Makarević, J.; Hudak, L.; Bartsch, G.; Haferkamp, A.; Wiesner, C.; Blaheta, R.A. HDAC inhibition suppresses bladder cancer cell adhesion to collagen under flow conditions. Exp. Biol. Med. 2013, 238, 1297–1304. [Google Scholar] [CrossRef] [PubMed]
- Lityńska, A.; Przybyło, M.; Pocheć, E.; Laidler, P. Adhesion properties of human bladder cell lines with extracellular matrix components: The role of integrins and glycosylation. Acta Biochim. Pol. 2002, 49, 643–650. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wu, G.; Yan, Y.; Zhou, Y.; Duan, Y.; Zeng, S.; Wang, X.; Lin, W.; Ou, C.; Zhou, J.; Xu, Z. Sulforaphane: Expected to become a novel anti-tumor compound. Oncol. Res. 2020. [Google Scholar] [CrossRef] [PubMed]
- Juengel, E.; Dauselt, A.; Makarević, J.; Wiesner, C.; Tsaur, I.; Bartsch, G.; Haferkamp, A.; Blaheta, R.A. Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells. Cancer Lett. 2012, 324, 83–90. [Google Scholar] [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Justin, S.; Rutz, J.; Maxeiner, S.; Chun, F.K.-H.; Juengel, E.; Blaheta, R.A. Bladder Cancer Metastasis Induced by Chronic Everolimus Application Can Be Counteracted by Sulforaphane In Vitro. Int. J. Mol. Sci. 2020, 21, 5582. https://doi.org/10.3390/ijms21155582
Justin S, Rutz J, Maxeiner S, Chun FK-H, Juengel E, Blaheta RA. Bladder Cancer Metastasis Induced by Chronic Everolimus Application Can Be Counteracted by Sulforaphane In Vitro. International Journal of Molecular Sciences. 2020; 21(15):5582. https://doi.org/10.3390/ijms21155582
Chicago/Turabian StyleJustin, Saira, Jochen Rutz, Sebastian Maxeiner, Felix K.-H. Chun, Eva Juengel, and Roman A. Blaheta. 2020. "Bladder Cancer Metastasis Induced by Chronic Everolimus Application Can Be Counteracted by Sulforaphane In Vitro" International Journal of Molecular Sciences 21, no. 15: 5582. https://doi.org/10.3390/ijms21155582